Boardroom Alpha
10-K primary document
LGVN · Annual Report (Form 10-K) · Filed March 17, 2026

Longeveron Inc10-K exhibit

lgvn-ex10_30.htm
EX-10.30

 

img180250435_0.jpg

 

Exhibit 10.30

 

September 3, 2025

Term Sheet for Interim Chief Executive Officer

 

Interim Role Details

Candidate: Than Powell
Position: Interim Chief Executive Officer
Reporting To: The Board of Directors
Effective Date: September 4, 2025
Duration: During the national CEO search which is anticipated to take approximately 6 months (and in no event to exceed 12 months).

Compensation, Equity and Benefits

Interim Base Salary: $500,000 annually, payable bi-weekly.
Interim Target Bonus Eligibility: 60% Eligible for prorated target bonus of base salary, subject to performance and Board approval. With respect to the Target Bonus, eighty percent (80%) of the Target Bonus amount will be based on the achievement of the performance goals presented by the CEO and approved by the Compensation Committee and/or Board for the applicable fiscal year, which may include both corporate goals and individual criteria; twenty percent (20%) of the Target Bonus amount will be at the discretion of the Board or the Compensation Committee.
Interim Equity Grant: You will receive a one-time grant on or about September 4, 2025, of 50,000 RSUs and 20,000 stock options. This Equity Award will have time-based vesting, and will vest 100% on the first anniversary of the date of grant
No changes to benefits, remain eligible to participate in standard company benefit programs (medical, dental, vision, 401(k), etc.) on same basis as other c-suite executives.

Other Terms

D&O Coverage: Covered under the Company’s D&O insurance.
Indemnification: Entitled to standard indemnification protections provided to officers.
Board Presence: As the interim CEO, you will have full access to the Board of Directors, including regular interactions and presence at the board meetings (excluding closed sessions), partnering with the Executive Chairman on board meeting agenda and content.

Termination

No changes to your at-will employment, terminable be either party.
Upon termination by the Company without Cause or by you for Good Reason:
o
You will receive your accrued salary, benefits, and reimbursable expenses.
o
Severance pursuant to agreement changed to three (3) months Base Salary for every year you worked full time for Longeveron and prorated for partial years (with a minimum of 3 months).
o
Three (3) months of COBRA pay for your current enrollment of medical, dental and vision plans.

Any remaining details will be worked out and agreed upon between the parties.

Signatures:

 

img180250435_1.jpg

 

img180250435_2.jpg

Longeveron Inc.

 

Employee

Josh Hare, Executive Chairman

 

Than Powell

 


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer